Arca
Skip to content
Tools
Tools

PDE10A: cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A

Plays a role in signal transduction by regulating the intracellular concentration of cyclic nucleotides.

  • Drugs that act on it: 4
  • Approved: 1
  • In phases 1 to 3: 3
  • Sponsors: 4

Who is on it, and how far along

Every drug ChEMBL records acting on PDE10A, by the furthest stage it has reached for any use, coloured by modality.

How to read this

Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.

  • Small molecule 4

Approved1

  • Ibudilast

Phase 30

    Phase 22

    • Balipodect
    • Mardepodect

    Phase 11

    • PBF-999

    Sponsors

    Drugs on this target per company: the US application holder, else the industry sponsor leading the most of its trials.

    • MediciNova125%
    • Palobiofarma SL125%

    The landscape

    Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials. All act as: Phosphodiesterase 10A inhibitor.
    IbudilastApprovedMediciNovaSmall moleculeInhibitor2
    BalipodectPhase 2Takeda Pharmaceuticals USASmall moleculeInhibitor0
    MardepodectPhase 2PfizerSmall moleculeInhibitor0
    PBF-999Phase 1Palobiofarma SLSmall moleculeInhibitor0

    Open trials

    The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 2 in all, from ClinicalTrials.gov.
    Ibudilast for Treating Alcohol Use DisorderIbudilastPhase 2Active, not recruitingUniversity of PennsylvaniaJun 10, 2022
    Evaluation of MN-166 (Ibudilast) for 12 Months Followed by an Open-label Extension for 6 Months in Patients With ALSIbudilastPhase 2 / Phase 3Active, not recruitingMediciNovaAug 15, 2019

    Diseases most associated with it

    Open Targets association score, 0 to 1; all associations
    • Infantile-onset generalized dyskinesia with orofacial involvement0.75
    • Striatal degeneration, autosomal dominant 20.69
    • Stroke disorder0.55
    • Hypothyroidism0.55
    • Coronary artery disorder0.54
    • Hypertensive disorder0.53
    • Cardiovascular disorder0.52
    • Thyroid gland disorder0.52
    • Hyperthyroidism0.52
    • Striatal degeneration, autosomal dominant0.48
    • Intermittent vascular claudication0.43
    • Autoimmune thyroid disease0.41

    Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL4409, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-21. Gene name, function (UniProt Q9Y233, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets

    Esc

    Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

    Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.